Table 2. Treatment of vascular risk factors prior to stroke among women with ischemic stroke covered by the URBMI/UEBMI and NRCMS.
| Treatment | Eligible population*, N (%) | Treatment | |||
|---|---|---|---|---|---|
| Total, N (%) | URBMI/UEBMI, N (%) | NRCMS, N (%) | P value | ||
| Antiplatelet | 5,707 (100.0) | 1,133 (19.9) | 633 (22.0) | 500 (17.7) | <0.0001 |
| Anticoagulation | 634 (11.1) | 44 (6.9) | 26 (7.2) | 18 (6.6) | 0.7481 |
| Anti-hypertension | 4,568 (80.0) | 2,891 (63.3) | 1,582 (68.3) | 1,309 (58.1) | <0.0001 |
| Lipid lowering drugs | 2,169 (38.0) | 403 (18.6) | 248 (22.6) | 155 (14.4) | <0.0001 |
| Anti-diabetics | 1,752 (30.7) | 1,084 (61.9) | 642 (65.0) | 442 (57.8) | 0.0019 |
*Eligible population indicates that the population is eligible for these drug treatments. NRCMS, New Rural Cooperative Medical Scheme; URBMI/UEBMI, urban resident/employee basic medical insurance.